Johnson & Johnson ( J&J ) has revealed that it has completed enrolment procedures for its efficacy trial of a HIV preventative vaccine from its subsidiary , Janssen . The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18 - 49 age range from five African countries with high HIV rates . The vaccine will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus , with the aim of triggering an immune response . If a safe and effective vaccine can be created , it could help to significantly reduce the rate of new infections , according to J&J.
Johnson & Johnson (J&J) has revealed that it has completed enrolment procedures for its efficacy study of a HIV preventative vaccine from its subsidiary, Janssen. The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18-35 age range from five African countries with high HIV rates. The treatment will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus, with the aim of triggering an immune response. If a safe and effective vaccine can be created, it could help to significantly reduce the rate of new infections, according to J&J.